TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females aged 18 to 65 years of age.~* A signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study including any known and potential risks and available alternative treatments.~* Subjects fulfilling criteria for episodic migraine as per the Second Edition of The International Headache Society (Olesen and Steiner 2004), who experience migraine at high frequency as follows:~  i. History of headaches on more than 8 days per month for at least 3 months prior to screening~ii. Verification of headache frequency through prospectively collected baseline information during the 28-day run-in phase demonstrating headaches (of any type) on at least 8 days with at total of 8 to 14 days\* fulfilling criteria for migraine.~\*Operational definition for migraine and probable migraine days are presented in the statistical section of this protocol.~* Body Mass Index (BMI) of 17.5 to 37.5 kg/m2, and a total body weight between 50 kg and 120 kg, inclusive.~* Demonstrated compliance with the electronic headache diary during the run-in period by entry of headache data on a minimum of 22/28 days (80% compliance).~Exclusion Criteria:~* Subject has received onabotulinum toxin A for migraine or for any medical or cosmetic reasons requiring injections in the head, face, or neck during the six months prior to screening.~* Subject uses medications containing opioids (including codeine) or barbiturates (including Fiorinal®, Fioricet®, or any other combination containing butalbital) on more than 4 days per month for the treatment of migraine or for any other reason.~* Failed \> 2 medication categories or \> 3 preventive medications (within two medication categories) due to lack of efficacy for prophylactic treatment of episodic or chronic migraine after an adequate therapeutic trial~* Treatment with an investigational drug or device within 30 days of study entry or any prior exposure to a monoclonal antibody targeting the CGRP pathway.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- LBR-101 High Dose (Type: EXPERIMENTAL): Subcutaneous High Dose LBR-101 Administered Monthly x 3
- LBR-101 Low Dose (Type: EXPERIMENTAL): Subcutaneous Low Dose LBR-101 Administered Monthly x 3
- Placebo (Type: PLACEBO_COMPARATOR): Subcutaneous Placebo Administered Monthly x 3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Treatment Adherence in HIV-Infected Individuals

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-infected~* English-speaking~* Currently receiving treatment at one of the participating sites~* Currently receiving antiretroviral therapy~Exclusion Criteria:~* Marked cognitive impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: OTHER): Participants will receive the control condition
- Intervention (Type: EXPERIMENTAL): Participants will receive the LifeWindows Intervention sessions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sodium NItroPrusside Treatment in Acute Heart Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* AHF diagnosis, defined as rapid onset or worsening of symptoms and/or signs of HF. According to a recently proposed new definition, HF is a clinical syndrome with current or prior Symptoms and or signs caused by a structural and/or functional cardiac abnormality (as determined by EF \<50%, abnormal cardiac chamber enlargement, E/E' \>15, moderate/severe ventricular hypertrophy or moderate/severe valvular obstructive or regurgitant lesion) and corroborated by at least one of the following: Elevated natriuretic peptide levels ; Objective evidence of cardiogenic pulmonary or systemic congestion by diagnostic modalities such as imaging (e.g. by chest X-ray or elevated filling pressures by echocardiography) or haemodynamic measurement (e.g. right heart catheterization, pulmonary artery catheter) at rest or with provocation (e.g. exercise).~* Intravenous SNP treatment~Exclusion Criteria:~* Age \<18 years old~* AHF after cardiac surgery~* AHF complicated by cardiogenic shock requiring high dosage (defined as inotropic score \>10) vasoactive agents and/or short-term extracorporeal life support (i.e. VA-ECMO, Impella). Inotropic score (IS) calculated as: dopamine dose (μg/kg/min) + dobutamine dose (μg/kg/min) + 100 × epinephrine dose (μg/kg/min) + 100 × norepinephrine dose (μg/kg/min) + 10 × phosphodiesterase 3 inhibitor dose (μg/kg/min).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acute heart Failure AHF (Type: None): AHF diagnosis, defined as rapid onset or worsening of symptoms and/or signs of HF

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Crohn's disease (CD) confirmed by endoscopy and histology~* Active disease as evaluated by Crohn's Disease Activity Index Score and Simple Endoscopic Score for CD~* Inadequate response to aminosalicylates, corticosteroids, immunomodulators or biologic therapy~Key Exclusion Criteria:~* Diagnosis of ulcerative colitis or indeterminate colitis~* Known strictures/stenosis leading to symptoms of obstruction~* Current stoma or need for ileostomy or colostomy~* Clinically relevant cardiovascular conditions or other relevant diseases that could impact the implementation or interpretation of the trial, or put the patient at risk~* History of uveitis or known macular edema~* History of colonic dysplasia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- RPC1063 (Ozanimod) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of choroidal neovascularization in patients with pseudoxanthoma elasticum~* Age between 18-65 years~* Patient must be able to follow protocol~* Written informed consent~* Genetic diagnosis of pseudoxanthoma elasticum~* Best corrected visual acuity between 20/200 - 20/32 in the treated eye~Exclusion Criteria:~* Patients who do not fulfill the inclusion criteria~* Patients with other retinal vascular diseases such as diabetic retinopathy or venous occlusive disease~* Ocular surgery 3 months before study enrollment~* History of uncontrolled glaucoma~* Active intraocular inflammation or inflammation of the ocular adnexa~* Subfoveal fibrosis in the study eye~* Inability to follow study protocol~* Major surgery one month before study enrollment~* History of severe cardiovascular disease or history of stroke 6 months before study enrollment~* Allergies against the substances or components of the study medication~* Low anticipated compliance~* Patients who participated in clinical trials simultaneously or within the last 60 days~* Pregnancy, lactation, women that may become pregnant and don't use safe contraception~* Chronic alcohol- or drug abuse within the last year~* Lacking legal competence or language ability~* Neurologic diseases such as multiple sclerosis~* Need of concomitant medication that is not allowed in combination with ranibizumab~* Previous intravitreal therapy with anti-angiogenic substances in the study eye within the last 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Colchicine to Prevent the Postpericardiotomy Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients in the third day after a cardiac surgery operation~* Age≥ 18 years~* Informed consent~Exclusion Criteria:~All evaluated before the surgical operation:~* Known severe liver disease and/or elevated transaminases \>1.5 times the upper limit of normality~* Serum creatinine \>2.5 mg/dl~* Serum creatine kinase (CK) over the upper limit of normality or known myopathy~* Known gastrointestinal or blood disease~* Pregnant or lactating women or women not protected by a contraception method~* Known hypersensibility to colchicine~* Treatment with colchicine at enrolment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years of age or older expected to undergo unilateral uncomplicated cataract extraction via phacoemulsification and posterior chamber intraocular lens implantation in one eye.~* Have a pin-hole corrected visual acuity without other correction of ≤ 1.3 logarithm of the minimum angle of resolution (logMAR) in the study eye to be operated and contralateral eye as measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart at Visit 1.~* Willing and able to comply with study requirements and visit schedule.~* Provide signed and dated informed consent.~Exclusion Criteria:~* Have a known sensitivity or allergy to clobetasol propionate, corticosteroids, or any of the study medication's components including benzalkonium chloride and soybean lecithin or any routine medication required during cataract surgery or for the conduct of study procedures~* Have an ACC count \> 0 or any evidence of intraocular inflammation (e.g., flare) in either eye at the Screening visit~* Have a Grade \> 0 on the Ocular Pain Assessment in either eye at the Screening visit~Note: Other inclusion/exclusion criteria apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- APP13007 0.05% BID (Type: EXPERIMENTAL): 1 drop APP13007 0.05% twice daily for 14 days to study (operated) eye
- Matching Vehicle Placebo (Type: PLACEBO_COMPARATOR): 1 drop matching vehicle placebo twice daily for 14 days to study (operated) eye

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antibody Persistence, Immune Response and Safety After Doses of Pentabio Vaccine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children, 18-24 months of age~* Subjects who had completed the primary series of Pentabio vaccine in the previous trial~* Father, mother, or legally acceptable representative have been informed properly regarding the study and signed the informed consent form~* Subject's parents commit to comply with the instruction~Exclusion Criteria:~* Subjects concomitantly enrolled or scheduled to be enrolled in another trial~* Evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature \>=37.5oC on Day 0)~* Known history of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection~* Known history of allergy to any component of the vaccines (e.f. formaldehyde)~* Known history of acquired immunodeficiency (including HIV infection)~* Subject who has received a treatment likely to alter immune response in the previous 4 weeks (e.g intravenous immunoglobulin, blood-derived products or long term corticotherapy (\>2 weeks)~* Subject receives other vaccination within 1 month prior to inclusion~* Any abnormality or chronic disease justified by investigator that might interfere assessment of the trial objectives~* Infant with a known history of diphtheria, tetanus, pertussis, Hepatitis B and Hib infection

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 24 Months
- Healthy Volunteers: t

Study Arms:
- Pentavalen (Type: EXPERIMENTAL): Pentabio Vaccine One dose corresponds to 0.5ml The vaccine shall be given intramuscularly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Popliteal Sciatic Nerve Block: Intraneural or Extraneural?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-II~Exclusion Criteria:~* Neurological diseases~* Diabetes~* Allergies to used drugs~* Chronic pain in treatment~* Electrophysiological alterations at time zero analysis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intraneural injection (Type: EXPERIMENTAL): All patients in the arm will receive a single intraneural injection of 12 ml Ropivacaine 1% BBraun, Germany, in the sciatic nerve under echographic guidance.
- extraneural injection (Type: ACTIVE_COMPARATOR): All patients in the arm will receive a single extraneural injection of 12 ml Ropivacaine 1% BBraun, Germany, around the sciatic nerve under echographic guidance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must provide written informed consent~* Eastern Cooperative Oncology Group performance status of at least 1~* Cytologically or histologically proven diagnosis of SCC of the penis~* Uni- or bidimensionally measurable disease as defined by RECIST v1.1 criteria~* Clinical stage N2-3 and/or M1 (TNM 2002)~* Locoregional relapse after prior major surgery/ies (either single or multiple)~* No prior systemic therapy except for the administration of vincristine-bleomycin-methotrexate (VBM) chemotherapy for superficial disease if administered at least 6 months prior to study enrollment~* Adequate bone marrow, liver and renal function~Exclusion Criteria:~* Central nervous system (CNS) metastases or leptomeningeal carcinomatosis~* History of active serious cardiovascular, cerebrovascular, pulmonary co-morbidities~* Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma or any cancer curatively treated \> 5 years prior to study entry.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Dacomitinib (PF-00299804) (Type: EXPERIMENTAL): PF-299804 will be administered orally at a dose of 45 mg/day continuously until surgery, evidence of disease progression or onset of unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Development and Validation of the Client Centered Occupational Therapy Service Model

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients diagnosed with schizophrenia according to DSM-5 diagnostic criteria.~2. Over 20 years old.~3. Agree to participate in the study~Exclusion Criteria:~* 1. Diagnosis of intellectual developmental disorders 2. History of severe brain injury 3. Cannot complete the study due to poor cognitive, vision or hand function

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Intervention Group (Type: EXPERIMENTAL): We will recruit 70 inpatients with schizophrenia and divided into intervention group and control group. The Intervention group provided Occupational therapy based on the MOHO theory, while the control group adopted the original Occupational therapy model.~The research at this stage is based on the theoretical framework of the MOHO model and the clinical practice of OTPF-3. Clinical experts are requested to assist in providing relevant suggestions as a reference for modifying intervention activities. Design OT@tcpc service model for occupational therapy intervention activities. The event design is based on the 4 systems of determinationl, habits, performance and environment, and 2 events are designed for each to be carried out in a group. Each activity includes 4 parts: warm-up, activity, feedback and homework. Each activity group will be explained separately so that the occupational therapist of the group can complete it under the guidance.
- Control Group (Type: ACTIVE_COMPARATOR): We will recruit 70 inpatients with schizophrenia and divided into intervention group and control group. The Intervention group provided Occupational therapy based on the MOHO theory, while the control group adopted the original Occupational therapy model.~This study was approved by the Institutional Review Board of Taipei City Hospital. After informed consent, the patients signed the consent form for this study and became the participant of this study.~Each activity group will be explained separately so that the participants of each group can complete it under the guidance. The group description includes: activity title, activity time (location), MOHO theory system, group purpose, activity content, equipment or materials, precautions, etc.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Grass pollen-related allergic rhinoconjunctivitis for at least the last two pollen seasons.~2. Positive SPT to grasses~3. Total symptoms score for the previous pollen season more than 12 out of 18.~4. Patients with FEV1 ≥ 80% of the predicted value.~Exclusion Criteria:~1. Positive SPT to other grasses present during the grass pollen season and if endemic to the region~2. Patients with clinically significant confounding symptoms of allergy to other allergens potentially overlapping the grass pollen season~3. Asthma requiring treatment with medications other than beta-2 inhaled agonists.~4. Patients who have received any desensitization treatment for grass pollen in the past 5 years.~5. Ongoing immunotherapy with any other allergen.~6. Patients with any nasal or oral condition that could confound the efficacy or safety assessments~7. Patients with known history of hypersensitivity or intolerance to any of the excipients in the investigational product (such as lactose intolerance).~8. Patients with any past or current clinically significant condition which as judged by the investigator, may affect the patient's participation or the outcome of the study.~9. Patients treated with systemic or inhaled corticosteroids~10. Patients treated or under treatment with beta-blockers, continuous systemic corticotherapy or immunosuppressive drugs.~11. Pregnant, breastfeeding, or sexually active women who are not using a medically accepted contraceptive method as listed above.~12. Patients participating or having participated within 30 days before Screening in any clinical study.~13. Patients who are unlikely to complete the study for any reason, or patients who have to travel for extended periods of time during the grass pollen season which will compromise the data~14. Patients with history of drug or alcohol abuse.~15. Study staff, investigators, sub-investigators, as well as their children or spouses and family members of all study staff should not be enrolled in the study.~16. Patients will not be randomized in this study more than once.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 300 IR (Type: EXPERIMENTAL): 300 IR grass pollen allergen extract tablet
- Placebo (Type: PLACEBO_COMPARATOR): Pacebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete